RT @tmprowell: Dr. Theodore Laetsch of @UTSouthwestern attributes efficiency of dev program targeting rare gene fusion in #cancer to intens…
Dr. Theodore Laetsch of @UTSouthwestern attributes efficiency of dev program targeting rare gene fusion in #cancer to intensive collaboration btwn clinicians, patients, sponsor, and regulators. @cddf_eu #CDDFalpine https://t.co/qDum45RuQy
RT @OncoblogBulbul: Pembro for MSI-H tumors (https://t.co/XfvjkJ7fIY…). Larotrectinib for TRK fusions (https://t.co/GJbRzUVy9T). This is…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
RT @OncoblogBulbul: Pembro for MSI-H tumors (https://t.co/XfvjkJ7fIY…). Larotrectinib for TRK fusions (https://t.co/GJbRzUVy9T). This is…
.#ONCOgenics Tumor está orientado específicamente a la identificación de todas aquellas alteraciones genéticas que pueden condicionar la sensibilidad o la resistencia a fármacos oncológicos aprobados para su uso clínico. Info: https://t.co/9WS73zQhXx https:/
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/0IkohRcIee
Larotrectinib, tropomyosin reseptör kinaz inhibitörünün faz1 çalışması. Yanıt oranı iyi ancak bakalım karşılaştırmalı çalışmalar ne gösterecek? https://t.co/jXStoBK0NP
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…
Efficacy of #Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/YuithGm9d8
Pembro for MSI-H tumors (https://t.co/XfvjkJ7fIY…). Larotrectinib for TRK fusions (https://t.co/GJbRzUVy9T). This is the future, treatments based on molecular features of the tumor, regardless of the anatomic location. Still in the very beginning, but t
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…
RT @VivekSubbiah: All the more reason to do “Universal genomic testing for cancer” https://t.co/7aBkMUr2c3 @JAMAOnc https://t.co/JDEsiIY87g
RT @VivekSubbiah: All the more reason to do “Universal genomic testing for cancer” https://t.co/7aBkMUr2c3 @JAMAOnc https://t.co/JDEsiIY87g
Making a difference in real actual lives - proud of @CleClinicMD @DavendraSohal coauthor of @NEJM study that has changed the lives of 2 of my patients who are incredibly grateful for their continuing responses and worst toxicity of broken fingernails #Prec
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
A wonderful example of precision oncology making real progress with a 75-80% response rate in targetted tumours https://t.co/CibvYu7aML
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/GfKjRWMlEi
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…
Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editorial: Developing Anticancer Drugs in Orphan Molecular Entities — A Paradigm under Construction https://t.co/m1zutQw1ci https://t
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
Impressive result . https://t.co/Ewn0kU0H0F
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
RT @VivekSubbiah: All the more reason to do “Universal genomic testing for cancer” https://t.co/7aBkMUr2c3 @JAMAOnc https://t.co/JDEsiIY87g
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
RT @VivekSubbiah: All the more reason to do “Universal genomic testing for cancer” https://t.co/7aBkMUr2c3 @JAMAOnc https://t.co/JDEsiIY87g
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
All the more reason to do “Universal genomic testing for cancer” https://t.co/7aBkMUr2c3 @JAMAOnc https://t.co/JDEsiIY87g
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA analysis. Any tumor type with NTRK fusion event appears likely to benefit. #precisionmedicine https://t.co/2qBmQBkLj9
Proud to be a part of this effort and lucky to work with this great team of people! @MSKPathology @sloan_kettering https://t.co/vG5jd4BTiU
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/X10Op6bFNr
#Larotrectinib eficaz en tumores con fusión de TRK (tropomyosin receptor kinases) positiva en niños (F. I-II) y adultos (F. II)➡️ TRO 75%; tras 1 año el 55% de los pacientes seguían libres de progresión 💊 https://t.co/m73F5N6EBW
2-0 precision medicine vs imprecision medicine https://t.co/AClvVXG0j8
Exciting data about TRK inhibition in human solid tumors published in @NEJM, includes CRC & PDAC patients. Potential treatment option for patients with rare (<1%) NTRK fusion https://t.co/DVNKpaBSoc
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @NReguart: Here it is!!! We were waiting for it, treating all cancers the same just based on a common genomic alteration, TRK-fusion. Ac…
RT @NReguart: Here it is!!! We were waiting for it, treating all cancers the same just based on a common genomic alteration, TRK-fusion. Ac…
another reason for routine molecular profilnig in all solid tumor malignancies - Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/qV5gyyga37
Ranging in age from 4 months to 76 years, were enrolled and treated. 😰😰 https://t.co/mZIbIr5aYx
Thérapie personnalisée en oncologie : efficacité du larotrectinib dans les tumeurs de l'adulte et de l'enfant porteuses d’une translocation impliquant TRK https://t.co/i3m40eMYdU via @NEJM #genomique #medecinedeprecision #cancer #cancerrare
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @StJudeResearch: Study shows larotrectinib had noticeable anti-tumor activity in patients with TRK fusion–positive cancer, including #ch…
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
Efficacy of #Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. @weldiery @FoxChaseCancer https://t.co/EULtMWXNbT
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @NReguart: Here it is!!! We were waiting for it, treating all cancers the same just based on a common genomic alteration, TRK-fusion. Ac…
Here it is!!! We were waiting for it, treating all cancers the same just based on a common genomic alteration, TRK-fusion. Access to precision medicine must be equative for all patients https://t.co/iP8McAB3QZ
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @DavidHongMD: Honored to have been a part of this landmark study! https://t.co/xttbXUaoCy
RT @JadeForster: precision medicine in action in clinical trials. https://t.co/aegUKNE4t4
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children #Pediatrics https://t.co/OdtKsEBu8x
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
precision medicine in action in clinical trials. https://t.co/aegUKNE4t4
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…